T1000	Speculation 672 679	whether
E1000	Speculation:T1000 Scope:T1001
T1001	Span 672 755	whether these glycans can modulate the neutralizing activity of anti-HCV antibodies
T1002	Speculation 505 513	suggests
E1001	Speculation:T1002 Scope:T1003
T1003	Span 505 648	suggests that these glycans can limit the immunogenicity of HCV envelope proteins and restrict the binding of some antibodies to their epitopes
T1004	Negation 1014 1017	not
E1002	Negation:T1004 Scope:T1005
T1005	Span 1014 1114	not find any evidence that N-linked glycans of E1 contribute to the masking of neutralizing epitopes
T1006	Speculation 867 880	evaluated for
E1003	Speculation:T1006 Scope:T1007
T1007	Span 867 999	evaluated for their sensitivity to neutralization by antibodies from the sera of infected patients and anti-E2 monoclonal antibodies
T1008	Speculation 1624 1638	indicates that
E1004	Speculation:T1008 Scope:T1009
T1009	Span 1624 1716	indicates that HCV glycans contribute to the evasion of HCV from the humoral immune response
T1010	Speculation 1454 1461	suggest
E1005	Speculation:T1010 Scope:T1011
T1011	Span 1454 1534	suggest that glycans E2N1, E2N6, and E2N11 are close to the binding site of CD81
